Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Eyenovia,_Inc.
|
| gptkbp:awards |
Research grants
Innovation awards |
| gptkbp:clinical_trial |
Ongoing
Phase 1 Phase 2 Phase 3 |
| gptkbp:collaborations |
Research institutions
|
| gptkbp:community_engagement |
Support groups
Educational initiatives Public awareness campaigns |
| gptkbp:focus |
Psychedelic medicine
|
| gptkbp:founded |
gptkb:2015
|
| gptkbp:founder |
Joseph A. De Simone
|
| gptkbp:future_plans |
Develop new products
Increase partnerships Enhance research capabilities Expand clinical trials |
| gptkbp:goal |
Improve mental health outcomes
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Microdose Therapeutics
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:innovation |
Novel drug formulations
|
| gptkbp:invention |
Drug delivery technologies
Psychedelic formulations |
| gptkbp:investment |
Venture capital firms
|
| gptkbp:marketing_strategy |
Research collaborations
Direct-to-consumer Partnerships with healthcare providers |
| gptkbp:partnership |
gptkb:University_of_California,_San_Diego
|
| gptkbp:philosophy |
Psychedelic-assisted therapy
|
| gptkbp:products |
Therapeutics
Psychedelic compounds |
| gptkbp:receives_funding_from |
gptkb:Series_A
gptkb:Series_B |
| gptkbp:regulatory_compliance |
Investigational New Drug (IND) application
|
| gptkbp:research_areas |
gptkb:Mental_health
|
| gptkbp:research_focus |
gptkb:Depression
Anxiety disorders PTSD Substance use disorders |
| gptkbp:safety_features |
Rigorous testing
|
| gptkbp:staff |
Experts in neuroscience
Experts in pharmacology Experts in psychiatry |
| gptkbp:target_market |
Patients with mental health disorders
|
| gptkbp:technology |
Microdosing delivery systems
|
| gptkbp:website |
www.microdosetherapeutics.com
|